Correlation between vaginal microbiota and cervical precancerous lesions
HAN Buwei1 LIU Yang1 HE Hui1 GONG Yi2 LIU Ning1 ZHOU Lina1 HAO Xinying1 LIU Li3
1.Graduate School of Heilongjiang University of Chinese Medicine, Heilongjiang Province, Harbin 150040, China;
2.Department of Traditional Chinese Medicine, Beilun Branch, the First Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang Province, Ningbo 315000, China;
3.Ward Two, Department of Gynecology, the First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Heilongjiang Province, Harbin 150040, China
Abstract：The female reproductive tract has a microbiome that lives in symbiosis with the human body, Lactobacillus is usually the dominant bacterium, this genus plays an important role in maintaining the health of the female reproductive tract. Dysregulation of reproductive tract microbiota may promote the development of human papillomavirus (HPV) infection and cervical intraepithelial neoplasias (CIN), and eventually lead to cervical malignancy. As the severity of CIN increases, depletion of dominant Lactobacillus increases, which may negatively affect the rate of disease regression, for example, leading to a pro-inflammatory environment that increases the expression of HPV E6 and E7 oncogenes and proliferation of malignant cells. This paper reviews the correlation between the composition of vaginal microbiota and the occurrence and development of cervical cancer, in order to better understand the influence of the microbiota on cervical cancer, which may contribute to explore new diagnostic or prognostic microbial markers of cervical cancer, and seek new prevention or treatment drug targets.
[1] Globocan （iARC） Section of Cancer Surveillance，Report No. 19/6/2017，2012.
[2] Desai S，Zhu MJ，Lapidos SI. Cervical cancer prevention：Human papillomavirus testing as primary screening [J]. Cancer，2022，128：939-943.
[3] Ventolini G，Vieira BP，De SF，et al. The Vaginal Microbiome：Ⅳ. The Role of Vaginal Microbiome in Reproduction and in Gynecologic Cancers [J]. J Low Genit Tract Dis，2022， 26：93-98.
[4] Stapleton AE，Au-Yeung M，Hooton TM，et al. Randomized，Placebo-Controlled Phase 2 Trial of a Lactobacillus Crispatus Probiotic Given Intravaginally for Prevention of Recurrent Urinary Tract Infection [J]. Clin Infect Dis，2021，52（10）：1212-1217.
[5] Hu SY，Hao YP，Zhang X，et al. Lacticaseibacillus casei LH23 Suppressed HPV Gene Expression and Inhibited Cervical Cancer Cells [J]. Probiotics Antimicrob Proteins，2021. DOI: 10.1007/s12602-021-09848-7. Epub ahead of print. PMID: 34599740.
[6] Moscicki AB，Schiffman M，Burchell A，et al. Updating the natural history of human papillomavirus and anogenital cancers [J]. Vaccine，2012，null：F24-33.
[7] Brusselaers N，Shrestha S，Van De Wijgert J，et al. Vaginal Dysbiosis and The Risk of Human Papillomavirus and Cervical Cancer：Systematic Review and Meta-Analysis [J]. Am J Obstet Gynecol，2019，221（1）：9-18.e8
[8] Doorbar J，Griffin H. Refining our understanding of cervical neoplasia and its cellular origins [J]. Papillomavirus Res，2019，7：176-179.
[9] Hwang LY，Scott ME，Ma YF，et al. Higher levels of cervicovaginal inflammatory and regulatory cytokines and chemokines in healthy young women with immature cervical epithelium [J]. J Reprod Immunol，2011，88：66-71.
[10] Ye JM，Wang CB，Wang DQ，et al. LncRBA GSA5，up- regulated byox-LDL，aggravates in flammatory response and MMP expression in THP-1 macrophages by acting like a sponge for miR-221 [J]. Exp Cell Res，2018，369（2）：348- 355.
[11] Muntinga CLP，de Vos van SPJ，Bekkers RLM，et al. Importance of the Immune Microenvironment in the Spontaneous Regression of Cervical Squamous Intraepithelial Lesions （cSIL） and Implications for Immunotherapy [J]. J Clin Med，2022，11：undefined.
[12] Scott ME，Ma YF，Farhat S，et al. Expression of nucleic acid-sensing Toll-like receptors predicts HPV16 clearance associated with an E6-directed cell-mediated response [J]. Int J Cancer，2015，136：2402-2408.
[13] Gustin AT，Thurman AR，Chandra N，et al. Recurrent bacterial vaginosis following metronidazole treatment is associated with microbiota richness at diagnosis [J]. Am J Obstet Gynecol，2022，226：225.e1-225.e15.
[14] Zheng N，Guo R，Wang J，et al. Contribution of Lactobacillus iners to Vaginal Health and Diseases：A Systematic Review [J]. Front Cell Infect Microbiol，2021，11：792787.
[15] Ravel J，Gajer P，Abdo Z，et al. Vaginal microbiome of reproductive-age women [J]. Proc Natl Acad Sci U S A，2011，null：4680-4687.
[16] Chaban B，Links MG，Jayaprakash TP，et al. Characterization of the vaginal microbiota of healthy Canadian women through the menstrual cycle [J]. Microbiome，2014，2：23.
[17] Gajer P，Brotman RM，Bai G，et al. Temporal dynamics of the human vaginal microbiota [J]. Sci Transl Med，2012，4：132ra52.
[18] Brotman RM，Ravel J，Bavoil PM，et al. Microbiome，sex hormones，and immune responses in the reproductive tract：challenges for vaccine development against sexually transmitted infections [J]. Vaccine，2014，32（14）：1543-1552.
[19] Marrazzo JM，Fiedler TL，Srinivasan S，et al. Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis [J]. J Infect Dis，2012，205（10）：1580- 1588.
[20] Kim MJ，Lee S，Kwon MY，et al. Clinical Significance of Composition and Functional Diversity of the Vaginal Microbiome in Recurrent Vaginitis [J]. Front Microbiol，2022， 13：851670.
[21] Zevin AS，Xie IY，Birse K，et al. Microbiome Composition and Function Drives Wound-Healing Impairment in the Female Genital Tract [J]. PLoS Pathog，2016，12：e1005889.
[22] Fernandes JV，Cobucci RNO，Jatobá CAN，et al. The role of the mediators of inflammation in cancer development [J]. Pathol Oncol Res，2015，21：527-534.
[23] Kyrgiou M，Moscicki A. Vaginal microbiome and cervical cancer [J]. Semin Cancer Biol，2022，undefined：undefined.
[24] Wei ZT，Chen HL，Wang CF，et al. Depiction of Vaginal Microbiota in Women With High-Risk Human Papillomavirus Infection [J]. Front Public Health，2020，8：587298.
[25] Norenhag J，Du J，Olovsson M，et al. The vaginal microbiota，human papillomavirus and cervical dysplasia：a systematic review and network meta-analysis [J]. BJOG，2020， 127：171-180.
[26] Godoy-Vitorino F，Romaguera J，Zhao C，et al. Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population [J]. Front Microbiol，2018，9：2533.
[27] Mitra A，MacIntyre DA，Paraskevaidi M，et al. The vaginal microbiota and innate immunity after local excisional treatment for cervical intraepithelial neoplasia [J]. Genome Med，2021，13：176.
[28] Liu CH，Chen Z，Chen K，et al. Lipopolysaccharide-Mediated Chronic Inflammation Promotes Tobacco Carcinogen-Induced Lung Cancer and Determines the Efficacy of Immunotherapy [J]. Cancer Res，2021，81（1）：144-157.
[29] Ilhan ZE，?覵aniewski P，Thomas N，et al. Deciphering the complex interplay between microbiota，HPV，inflammation and cancer through cervicovaginal metabolic profiling [J]. E Bio Medicine，2019，44：675-690.
[30] Federico A，Morgillo F，Tuccillo C，et al. Chronic inflammation and oxidative stress in human carcinogenesis [J]. Int J Cancer，2007，121：2381-2386.
[31] Hayes JD，Dinkova-Kostova AT，Tew KD. Oxidative Stress in Cancer [J]. Cancer Cell，2020，38（2）：167-197.
[32] De Marco F. Oxidative Stress and HPV Carcinogenesis [J]. Viruses，2013，5（2）：708-731.
[33] Georgescu SR，Mitran CL，Mitran MI，et al. New Insights in the Pathogenesis of HPV Infection and the Associated Carcinogenic Processes：The Role of Chronic Inflammation and Oxidative Stress [J]. J Immunol Res，2018，2018：5315816.
[34] Lebeau A，Bruyere D，Roncarati P，et al. HPV infection alters vaginal microbiome through down-regulating host mucosal innate peptides used by Lactobacilli as amino acid sources [J]. Nat Commun，2022，13：1076.
[35] Kyrgiou M，Mitra A，Moscicki AB. Does The Vaginal Microbiota Play a Role in The Development of Cervical Cancer? [J]. Transl Res，2017，179：168-182.
[36] Doorbar J. Model Systems of Human Papillomavirus-Associated Disease [J]. J Pathol，2016，238（2）：166-179.
[37] Allen-Hoffmann BL，Schlosser SJ，Ivarie CA，et al. Normal Growth and Differentiation in a Spontaneously Immortalized Near-Diploid Human Keratinocyte Cell Line，Niks [J]. J Investig Dermatol，2000，114（3）：444-455.
[38] Zehbe I，Lichtig H，Westerback A，et al. Rare human papillomavirus 16 E6 variants reveal significant oncogenic potential [J]. Mol Cancer，2011，10：77.
京公网安备 11010502046598号